Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pain and Therapy
Published in: Pain and Therapy 1/2018

Open Access 01-06-2018 | Review

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain

Authors: Joseph V. Pergolizzi Jr, Robert Taylor Jr, Jo Ann LeQuang, Robert B. Raffa, John Bisney

Published in: Pain and Therapy | Issue 1/2018

Login to get access

Abstract

Tapentadol is a novel pain reliever with apparently synergistic dual mechanisms of action, capable of addressing both nociceptive and neuropathic components of chronic pain. As an effective analgesic with good tolerability, tapentadol may be appropriate for patients suffering from severe chronic pain associated with low back pain (LBP) or osteoarthritis (OA). Efficacy studies of tapentadol in populations of patients with severe chronic LBP or OA pain suggest that tapentadol is non-inferior to oxycodone. Its tolerability, especially with respect to gastrointestinal (GI) side effects, may be better than that of other strong opioids in clinical trials and analyses of multiple trials. Patient satisfaction with tapentadol extended release for chronic noncancer pain syndromes is good. Although tapentadol has an opioid component with abuse liability, it appears to be a difficult opioid for tampering with less appeal to abusers than other opioids. For patients with severe LBP and OA pain, tapentadol appears to hold promise as a safe, effective therapeutic option.
Literature
1.
2.
3.
4.
5.
6.
Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging. 2005;22(8):641–54.CrossRefPubMed
7.
Centers for Disease C, Prevention. CDC grand rounds: prescription drug overdoses—a US epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.
8.
Dowell D, Haegerich T. R C. CDC Guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.CrossRefPubMed
9.
Pergolizzi JV Jr, Raffa RB, LeQuang JA. The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused? J Clin Pharm Ther. 2016;41(6):592–3.CrossRefPubMed
10.
11.
Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11(11):1230–9.CrossRefPubMed
12.
13.
14.
15.
Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain (London, England). 2010;14(8):781–83.
16.
17.
Pergolizzi J, Alon E, Baron R, et al. Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? J Pain Res. 2011;4:203–10.PubMedPubMedCentral
18.
19.
Games G, Hutchison A. Tapentadol-ER for the treatment of diabetic peripheral neuropathy. Consult Pharm. 2013;28(10):672–5.CrossRefPubMed
20.
Kern KU, Bialas P, Fangmann D. Prolonged-release tapentadol for phantom pain. A case series. Schmerz (Berlin, Germany). 2013;27(2):174–81.
21.
Taylor R, Pergolizzi JV, Raffa RB. Tapentadol extended release for chronic pain patients. Adv Ther. 2013;30(1):14–27.CrossRefPubMed
22.
23.
Torres-Sanchez S, Alba-Delgado C, Llorca-Torralba M, Mico JA, Berrocoso E. Effect of tapentadol on neurons in the locus coeruleus. Neuropharmacology. 2013;72:250–8.CrossRefPubMed
24.
Christoph T, Schroder W, Tallarida RJ, De Vry J, Tzschentke TM. Spinal-supraspinal and intrinsic mu-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther. 2013;347(3):794–801.CrossRefPubMed
25.
26.
Tzschentke TM, Folgering JH, Flik G, De Vry J. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci Lett. 2012;507(2):151–5.CrossRefPubMed
27.
Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011;337(1):312–20.CrossRefPubMedPubMedCentral
28.
Gohler K, Brett M, Smit JW, Rengelshausen J, Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013;51(4):338–48.CrossRefPubMed
29.
30.
Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects. J Opioid Manag. 2013;9(4):291–300.CrossRefPubMed
31.
Yarnitsky D, Arendt-Nielsen L, Bouhassira D, et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur J Pain (London, England). 2010;14(4):339.
32.
Yarnitsky D, Granot M, Granovsky Y. Pain modulation profile and pain therapy: between pro- and antinociception. Pain. 2014;155(4):663–5.CrossRefPubMed
33.
Martini C, van Velzen M, Drewes A, Aarts L, Dahan A, Niesters M. A randomized controlled trial on the effect of tapentadol and morphine on conditioned pain modulation in healthy volunteers. PLoS One. 2015;10(6):e0128997.CrossRefPubMedPubMedCentral
34.
Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev (Online). 2007(3):CD004959.
35.
Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev (Online). 2013;8:CD004959.
36.
Baron R, Likar R, Martin-Mola E, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Pract. 2016;16(5):580–99.CrossRefPubMed
37.
Baron R, Jansen JP, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract. 2016;16(5):600–19.CrossRefPubMed
38.
Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505.CrossRefPubMed
39.
Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787–804.CrossRefPubMed
40.
Kavanagh S, Kwong WJ, Hammond GC, Nelson W, Upmalis D, Yang M. Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain. Pain Med (Malden, Mass). 2012;13(9):1110–20.
41.
Baron R, Kern U, Muller M, Dubois C, Falke D, Steigerwald I. Effectiveness and tolerability of a moderate dose of tapentadol prolonged release for managing severe, chronic low back pain with a neuropathic component: an open-label continuation arm of a randomized phase 3b study. Pain Pract. 2015;15(5):471–86.CrossRefPubMed
42.
Steigerwald I, Schenk M, Lahne U, Gebuhr P, Falke D, Hoggart B. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig. 2013;33(9):607–19.CrossRefPubMedPubMedCentral
43.
Galvez R, Schafer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther. 2013;30(3):229–59.CrossRefPubMed
44.
Steigerwald I, Muller M, Kujawa J, Balblanc JC, Calvo-Alen J. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J Pain Res. 2012;5:121–38.CrossRefPubMedPubMedCentral
45.
Santos J, Alarcao J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev (Online). 2015;5:CD009923.
46.
Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27–40.PubMed
47.
Etropolski M, Lange B, Goldberg J, Steup A, Rauschkolb C. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. J Opioid Manag. 2013;9(5):343–56.CrossRefPubMed
48.
Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin. 2011;27(10):1907–30.CrossRefPubMed
49.
Freynhagen R, Baron R, Gockel U, Tolle T. painDETECT: a new screening quesitonnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911–20.CrossRefPubMed
50.
Baron R, Binder A, Attal N, Casale R, Dickenson AH, Treede RD. Neuropathic low back pain in clinical practice. Eur J Pain (London, England). 2016;20(6):861–73.
51.
Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14.CrossRefPubMedPubMedCentral
52.
Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: a review. Pain Med (Malden, Mass). 2002;3(3):260–71.
53.
Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain (London, England). 2008;12(6):804–13.
54.
Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–62.CrossRefPubMed
55.
Schwittay A, Schumann C, Litzenburger BC, Schwenke K. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists. J Pain Palliat Care Pharmacother. 2013;27(3):225–34.CrossRefPubMed
56.
Lerner D, Chang H, Rogers WH, et al. Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain. J Occup Environ Med. 2012;54(8):933–8.CrossRefPubMed
57.
Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2–guidance. Pain Physician. 2012;15(3 Suppl):S67–116.PubMed
58.
Boudreau D, Von Korff M, Rutter C, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18:1165–75.
59.
Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27(6):381–99.CrossRefPubMed
60.
Steigerwald I, Muller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28(6):911–36.CrossRefPubMed
61.
Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416–27.CrossRefPubMed
62.
Etropolski M, Van Hove I, Ashworth J, Haufel T. Effiacy and tolerability of tapentadol extended release (ER) in patients with moderate to severe osteoarthritis or low back pain over 2 years of treatments. In: 64th Annual Postgraduate Assembly in Anesthesiology (PGA); December 10–14, 2010; New York, NY.
63.
Sanchez Del Aguila MJ, Schenk M, Kern KU, Drost T, Steigerwald I. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther. 2015;37(1):94–113.CrossRefPubMed
64.
65.
Pergolizzi J, Alegre C, Blake D, et al. Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pain Pract. 2012;12(4):290–306.CrossRefPubMed
66.
Varrassi G, Marinangeli F, Piroli A, Coaccioli S, Paladini A. Strong analgesics: working towards an optimal balance between efficacy and side effects. Eur J Pain (London, England). 2010;14(4):340–42.
67.
Merker M, Dinges G, Koch T, Kranke P, Morin AM. Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies. Schmerz (Berlin, Germany). 2012;26(1):16–26.
68.
Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014;17(4):329–43.PubMed
69.
Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–49.CrossRefPubMed
70.
71.
Hartrick CT, Rozek RJ. Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011;25(5):359–70.CrossRefPubMed
72.
73.
Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anesthesiol. 2005;71:425–33.
74.
75.
Xu XS, Etropolski M, Upmalis D, Okamoto A, Lin R, Nandy P. Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR. Pharm Res. 2012;29(9):2555–64.CrossRefPubMed
76.
Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28(5):401–17.CrossRefPubMed
77.
Kwong WJ, Hammond G, Upmalis D, Okamoto A, Yang M, Kavanagh S. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain. Clin J Pain. 2013;29(8):664–72.CrossRefPubMed
78.
Vorsanger G, Xiang J, Okamoto A, Upmalis D, Moskovitz B. Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. J Opioid Manag. 2010;6(3):169–79.CrossRefPubMed
79.
Eichenbaum G, Gohler K, Etropolski M, et al. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. J Opioid Manag. 2015;11(3):211–27.CrossRefPubMed
80.
Merchant S, Provenzano D, Mody S, Ho KF, Etropolski M. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies. J Opioid Manag. 2013;9(1):51–61.CrossRefPubMed
81.
Vorsanger GJ, Klopfer AM, Xiang J, Benson CJ, Moskovitz BL, Rosenthal NR. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study. J Opioid Manag. 2013;9(4):281–90.CrossRefPubMed
82.
83.
84.
Cepeda M, Fife D, Vo L, Mastrogiovanni G, Yuan Y. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study. J Pain Palliat Care Pharmacother. 2013;14:158–64.
85.
Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs. 2012;72(13):1713–23.CrossRefPubMed
86.
Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013;130(1–3):13–23.CrossRefPubMed
87.
88.
Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin(R) (non-TRF) in prescription opioid abusers. Addiction (Abingdon, England). 2013;108(6):1095–1106.
89.
90.
Janssen Ortho L. Nucynta 50 mg, tapentadol tablet. Gurabo, PR, USA; 2010.
91.
Biondi DM, Xiang J, Etropolski M, Moskovitz B. Tolerability and efficacy of tapentadol extended release in elderly patients >/= 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015;11(5):393–403.CrossRefPubMed
92.
Vorsanger G, Xiang J, Biondi D, et al. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients. Pain Res Manag journal de la societe canadienne pour le traitement de la douleur. 2011;16(4):245–51.
93.
Biondi DM, Xiang J, Etropolski M, Moskovitz B. Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. Clin Drug Investig. 2014;34(8):565–76.CrossRefPubMedPubMedCentral
Metadata
Title
Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
Authors
Joseph V. Pergolizzi Jr
Robert Taylor Jr
Jo Ann LeQuang
Robert B. Raffa
John Bisney
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 1/2018
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-018-0095-8

Other articles of this Issue 1/2018

Pain and Therapy 1/2018 Go to the issue

Review

Behavioral Therapy Approaches for the Management of Low Back Pain: An Up-To-Date Systematic Review

Brief Report

Pain Agreements and Healthcare Utilization in a Veterans Affairs Primary Care Population: A Retrospective Chart Review

Review

A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review

Review

A Brief History of the Opioid Epidemic and Strategies for Pain Medicine

Review

A Review of the Opioid Epidemic: What Do We Do About It?

Review

Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits